AUG 07, 2018 8:30 PM PDT

Potential Bcl-2 Targeted Therapy for Relapsed Multiple Myeloma Patients

WRITTEN BY: Mauri Brueggeman

In June 2018, a new first of its kind drug class for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) was approved by the Food and Drug Administration in the United States.  The target of this new drug class is Bcl-2, which is an apoptotic, or programmed cell death, regulator.  Bcl-2 controls cell death through mitochondrial membrane permeability mechanisms with caspases.  Bcl-2 is located on chromosome 18, and is considered an oncogene; this sequence can, and is, involved in translocations or mutations resulting in deregulation of expression in tumorigenesis.  Tumor cells must survive inhospitable conditions including hypoxia and loss of nutrient supply when they become advanced enough; each of these contribute to tumor cell damage susceptibility and apoptosis.  Tumor cells must adapt by gaining mutations that inhibit that apoptotic process which is what happens with Bcl-2 mutations. 

Bcl-2 family members, there are reported to be about 20 total related proteins, act to create protein channels or pores within the mitochondrial membrane allowing the release of factors like Cytochrome C.  These factors are intermediaries as part of one apoptotic pathway.  When Bcl-2 expression is affected by mutation, these factors cannot be released as a part of the apoptosis mechanism of the cell.

In mutated lymphocytic cells, there is high level of expression of proapoptotic proteins at the ready but they are stuck waiting by the blocked Bcl-2 pathway.  Patients with these primed mutated lymphocytes, like those with CLL, readily die when another apoptotic agent outside of that Bcl-2 mediated pathway is introduced in conjunction with this new drug class. 

Additional investigations are being made using Bcl-2 targeted drugs for other conditions like Multiple Myeloma (MM), which does not involve an altered chromosome 18; MM cells are plasma cells with a translocation between chromosomes 11 and 14.  However, one group of researchers published their investigation in Leukemia on August 3, 2018.  MM patients have overexpression of anti-apoptotic proteins like Bcl-2; they found that combination therapy which included venetoclax, the Bcl-2 targeted drug approved by the FDA in June, had a promising response rate in relapsed myeloma patients.  This type of pretreated myeloma patient has few options for disease free survival long term.  This new approach may prove to be clinically relevant in the near future after further research is conducted.  

Sources: Leukemia, Blood, FDA, BBA Molecular Cell Research,

About the Author
MEd
Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
MAY 02, 2022
Cancer
Prostate Cancer: What's in a Name?
MAY 02, 2022
Prostate Cancer: What's in a Name?
Hearing the word “cancer” could have a significant psychological impact on a patient waiting on a diagnosis. ...
MAY 12, 2022
Cancer
Crisis in Ukraine Disrupts Delivery of Critical Cancer Care
MAY 12, 2022
Crisis in Ukraine Disrupts Delivery of Critical Cancer Care
Many factors including the type of cancer, pathologic stage, and the general health and demographics of the patient, dic ...
JUN 09, 2022
Cancer
A Case Study May Identify a Novel Gene Therapy for Pancreatic Cancer
JUN 09, 2022
A Case Study May Identify a Novel Gene Therapy for Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive pancreatic cancer with limited treatment options.  PDA ...
JUN 20, 2022
Cancer
Uterine Cancer Mortality is on the Rise
JUN 20, 2022
Uterine Cancer Mortality is on the Rise
Uterine cancer develops when cells in the inner lining of the uterus, known as the endometrium, undergo uncontrolled and ...
JUN 27, 2022
Technology
Machine Learning Predicts Which Genetic Mutations Drive Cancer Progression
JUN 27, 2022
Machine Learning Predicts Which Genetic Mutations Drive Cancer Progression
Understanding what drives cancer has perplexed scientists for years. However, what is abundantly clear is that mutations ...
JUL 28, 2022
Cancer
Potential Marker for Prostate Cancer Prognosis Identified
JUL 28, 2022
Potential Marker for Prostate Cancer Prognosis Identified
Cytokines, proteins that affect the immune system, can elicit their effects in either a beneficial or an inhibitory capa ...
Loading Comments...